In this powerful episode of Global Market Bulletin TV, host Leyla Gulen sits down with Greg Mayes, President and CEO of Reunion Neuroscience (NASDAQ: REUN), for an exclusive and forward-looking conversation that brings viewers inside one of the most innovative companies in the emerging field of next-generation psychedelic therapeutics.
The discussion opens with a major organizational milestone: the appointment of Robert Alexander, M.D., a seasoned neuroscience and clinical development expert, as Chief Medical Officer. Mayes explains how Dr. Alexander’s extensive background in CNS drug development strengthens Reunion’s scientific leadership as the company accelerates into Phase 2 planning and expands its pipeline through its differentiated RE200 series.
A key highlight of the interview centers on Reunion’s latest achievement—the completion and analysis of the Phase 1 clinical trial for their lead asset RE104, an exclusive 4-OH-DiPT prodrug engineered to deliver potent, rapid-acting, and durable serotonergic psychedelic effects. Mayes provides new insights into the safety, tolerability, and pharmacokinetic profile observed in Phase 1, positioning RE104 as a potentially transformative treatment for one of the most underserved patient populations: women suffering from postpartum depression (PPD).
Mayes speaks candidly about the severe unmet medical need in PPD, outlining what he calls “one of the greatest market opportunities in modern psychiatry.” Current treatments are slow, limited, or burdensome, often leaving mothers without rapid relief during one of the most critical periods in family health. RE104’s design—combining fast-acting symptom reduction with durable therapeutic effects—could disrupt the entire treatment landscape and offer a new path forward for millions of women worldwide.
The conversation also introduces viewers to Reunion’s RE200 series, a suite of next-generation serotonergic psychedelic compounds designed with improved receptor selectivity and differentiated pharmacology. These programs aim to unlock new therapeutic indications where precision modulation of serotonin pathways may offer substantial clinical benefit.
With clarity and conviction, Greg Mayes outlines Reunion’s broader vision: to create cutting-edge, science-driven psychedelic therapeutics that deliver meaningful and lasting improvements to patients with historically overlooked mental health conditions. From strategic clinical planning to intellectual property leadership—supported by U.S. Patent No. 11,292,765 securing RE104 and RE200 through 2041—Reunion is positioning itself as one of the most advanced and scientifically rigorous companies in the psychedelic medicine sector.
This Global Market Bulletin TV interview is essential viewing for investors, clinicians, policymakers, and anyone following the future of neuropsychiatric drug development.
Be sure to Subscribe and activate notifications to stay ahead of market-moving interviews and emerging biotech features.
CHECK THIS OUT: Why Nebius (NBIS) Could Outperform CoreWeave & Dominate the $9B AI Infrastructure Market and Is Lucid Group (LCID) Running Out of Cash? $875M Note Deal Raises Alarms.
About Reunion Neuroscience (NASDAQ: REUN)
Reunion Neuroscience is a clinical-stage biotechnology company dedicated to developing next-generation serotonergic psychedelic therapeutics for underserved mental health conditions. The company is advancing RE104, a proprietary 4-OH-DiPT prodrug designed to deliver rapid, durable symptom relief for patients with postpartum depression (PPD)—a condition with profound personal, familial, and societal impact and limited effective treatments.
Reunion’s scientific innovation is supported by robust patent protection, including U.S. Patent No. 11,292,765, which grants composition-of-matter and manufacturing protection for RE104 and its hemi-ester tryptamine class through June 2041. The company’s RE200 series, currently in preclinical development, is aimed at creating selective, next-generation psychedelic compounds capable of addressing additional psychiatric and neurological disorders where receptor specificity can enhance therapeutic outcomes.
Through rigorous science, clinical precision, and a mission focused on improving lives, Reunion Neuroscience is leading the way in developing safe, controlled, and highly targeted psychedelic-based treatments that push mental health innovation into a new era.
READ ALSO: Above Food (ABVE) to Issue 1.1 Billion New Shares in Merger and Perpetua Resources (PPTA) Soars 171% as U.S. Approves $1.3B Gold-Antimony Mine.
